FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to an antibody-drug conjugate (ADC) with a high ratio of drug to antibody, and a pharmaceutical composition for treating cancer, methods for treating cancer and inhibiting the growth or progression of a tumour.
EFFECT: use of the invention allows to obtain an ADC with a high drug loading, which has a higher efficiency in vivo and less nonspecific cytotoxicity in vitro compared to traditional high-load ADCs that use maleimide bond.
27 cl, 12 tbl, 15 ex, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF ANTIBODY AND DRUG, COMPOSITIONS BASED ON SAID CONJUGATE AND METHODS OF PRODUCING SAID CONJUGATE | 2015 |
|
RU2728235C2 |
| HOMOGENEOUS ANTIBODY AND DRUG CONJUGATES PRODUCED BY ENZYMATIC METHODS | 2015 |
|
RU2796266C2 |
| THERAPEUTIC ANTIBODIES AND THEIR APPLICATION | 2016 |
|
RU2722381C2 |
| STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | 2015 |
|
RU2680238C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
